Check out the full company presentation here.
Right now, IMMX has several potential catalysts that could fuel this profile towards a vertical move near term. And none may be more important than this one...
IMMX No 1. Potential Catalyst - U.S. FDA Grants Orphan Dr-ug Designation
ImmixBio Announces FDA Orphan Dr-ug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma
LOS ANGELES, Sept. 30, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)™ for oncology and inflammation, today announced that the U.S. Food and Dr-ug Administration (FDA) has granted orphan dr-ug designation (ODD) to IMX-110 for the treatment of soft tissue sarcoma.
The FDA’s Office of Orphan Products Development grants orphan designation status to dr-ugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Dr-ug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to 7 years of market exclusivity in the U.S. upon regulatory approval.
“We are pleased to receive FDA’s orphan dr-ug designation in soft tissue sarcoma for IMX-110, the first clinical-stage product of our SMARxT Tissue-Specific Platform,” said Ilya Rachman MD PhD, ImmixBio Founder & CEO. “We are thrilled to potentially contribute to expanding therapeutic options for oncology patients, beginning with soft tissue sarcoma.”
Gabriel Morris, ImmixBio Chief Financial Officer, added: “Orphan dr-ug designation for IMX-110 represents a substantial value creating step along our path of building a strong, independent biopharmaceutical organization.”
Read the full article here.
IMMX No 2. Potential Catalyst - A Crazy Low Float
According to the Yahoo Finance website, IMMX has a tiny float.
The website reports this profile to have approximately 1.29Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts could help spark a vertical move in the short-term.
IMMX No 3. Potential Catalyst - IPO And Joining The NasdaqCM
Immix Biopharma, Inc. Announces Closing of Initial Public Offering
LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common st-ock at a public offering price of $5.00 per share, for gross proceeds of $21Mn, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares of common st-ock at the initial public offering price, less the underwriting discount, to cover over-allotments.
The shares began trading on the Nasdaq Capital Market on December 16, 2021 under the ticker symbol “IMMX.”
ThinkEquity acted as sole book-running manager for the offering.
The Company intends to use the net proceeds from the offering to fund a planned IMX-110 Phase 2a clinical trial in soft tissue sarcoma and IMX-110 + tislelizumab Phase 1b combination trial, for IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease), and for working capital and other general corporate purposes.
Read the full article here.
IMMX No 4. Potential Catalyst - Company Nears Phase 2a Trials
The company plans to treat even more STS patients in a Phase 2a trial with IMX-110 as a first-line therapy. The rationale for that includes: (2)
- Encouraging clinical trial and tolerability data in its IMX-110 Phase 1b escalation trial
- Precedent US FDA clinical trial design for a first line treatment
- Interest from leading STS principal investigators
Given IMX-110’s novel feature of co-delivery of a resistance-suppressing poly-kinase inhibitor with an apoptosis inducer, the company believes IMX-110 can be used for treatment-resistant STS and other advanced, treatment-resistant cancers.
Even better, IMX-110 represents a paradigm shift away from a focus on cytotoxic or targeted therapies alone which, while producing initial tumor shrinkage, simultaneously activate pathways that lead to cancer relapse and treatment resistance.
More details here.
IMMX Complete Recap - 4 Potential Catalysts Lead The Way
No 1. - U.S. FDA Grants Orphan Dr-ug Designation
No 2. - A Crazy Low Float
No 3. - IPO And Joining The NasdaqCM
No 4. - Company Nears Phase 2a Trials
Coverage is officially initiated on IMMX. When you have time later, do this: